Paul Russo

List of Publications by Year
in descending order

Version: 2024-02-01

198 papers	11,810 citations	53794 45 h-index	31849 101 g-index
211 all docs	211 docs citations	211 times ranked	14087 citing authors

#	Article	IF	Citations
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
2	Epidemiology of Renal Cell Carcinoma. European Urology, 2019, 75, 74-84.	1.9	917
3	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231.	8.8	746
4	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3916-3923.	1.6	316
5	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 668-680.	1.6	262
6	The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer, 1998, 82, 389-394.	4.1	251
7	Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. European Urology, 2016, 69, 646-657.	1.9	249
8	A role for neoadjuvant gemcitabine plus cisplatin in muscleâ€invasive urothelial carcinoma of the bladder. Cancer, 2008, 113, 2471-2477.	4.1	239
9	Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndromeâ€“associated Renal Cancer. American Journal of Surgical Pathology, 2014, 38, 627-637.	3.7	223
10	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
11	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research, 2014, 20, 1955-1964.	7.0	208
12	CKD and the Risk of Incident Cancer. Journal of the American Society of Nephrology: JASN, 2014, 25, 2327-2334.	6.1	207
13	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. European Urology, 2015, 68, 980-992.	1.9	206
14	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. Cancer Cell, 2021, 39, 662-677.e6.	16.8	179
15	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications, 2016, 7, 13131.	12.8	140
16	Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979â€“1989). Cancer, 1991, 67, 1305-1310.	4.1	127
17	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Modern Pathology, 2015, 28, 845-853.	5.5	127
18	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncology, The, 2020, 21, 283-293.	10.7	121

#	Article	IF	Citations
19	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer, 1990, 66, 2476-2481.	4.1	119
20	Chromophobe Renal Cell Carcinoma. American Journal of Surgical Pathology, 2011, 35, 962-970.	3.7	115
21	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer, 1992, 69, 550-556.	4.1	105
22	MULTIPLE PRIMARY MALIGNANCIES IN RENAL CELL CARCINOMA. Journal of Urology, 1998, 160, 1255-1259.	0.4	98
23	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. Journal of Urology, 2003, 169, 177-181.	0.4	97
24	Sarcomatoid-variant Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 454-459.	1.3	91
25	Pathologic findings at the time of nephrectomy for renal mass. Annals of Surgical Oncology, 1997, 4, 570-574.	1.5	90
26	Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight, 2017, 2, .	5.0	89
27	Cytoreductive Nephrectomy â€" Patient Selection Is Key. New England Journal of Medicine, 2018, 379, 481-482.	27.0	88
28	Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer, 2008, 113, 84-96.	4.1	85
29	The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The memorial sloan-kettering cancer center experience. Cancer, 1994, 73, 3020-3028.	4.1	84
30	Nephrectomy during operative management of retroperitoneal sarcoma. Annals of Surgical Oncology, 1997, 4, 421-424.	1.5	82
31	Histopathologic and Ultrastructural Correlates of Tumor Growth Suppression by High Energy Shock Waves. Journal of Urology, 1987, 137, 338-341.	0.4	79
32	Bilateral non-familial renal cell carcinoma. Annals of Surgical Oncology, 1998, 5, 548-552.	1.5	77
33	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. European Urology, 2014, 66, 577-583.	1.9	76
34	Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology, 2020, 17, 659-678.	3.8	76
35	Management of Small Kidney Cancers in the New Millennium. JAMA Surgery, 2015, 150, 664.	4.3	75
36	An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. European Urology, 2016, 69, 72-79.	1.9	75

#	Article	IF	Citations
37	The Medical and Oncological Rationale for Partial Nephrectomy for the Treatment of T1 Renal Cortical Tumors. Urologic Clinics of North America, 2008, 35, 635-643.	1.8	70
38	Partial nephrectomy: The rationale for expanding the indications. Annals of Surgical Oncology, 2002, 9, 680-687.	1.5	64
39	The Type of Urinary Diversion After Radical Cystectomy Significantly Impacts on the Patient?s Quality of Life. Annals of Surgical Oncology, 2000, 7, 4-8.	1.5	62
40	Use of DWI in the Differentiation of Renal Cortical Tumors. American Journal of Roentgenology, 2016, 206, 100-105.	2.2	61
41	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nature Communications, 2017, 8, 15165.	12.8	61
42	End Stage and Chronic Kidney Disease: Associations with Renal Cancer. Frontiers in Oncology, 2012, 2, 28.	2.8	56
43	Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 259.e1-259.e8.	1.6	56
44	Urinary Diversion After Total Pelvic Exenteration for Rectal Cancer. Annals of Surgical Oncology, 1999, 6, 732-738.	1.5	54
45	Ureteral decompression in advanced nonurologic malignancies. Annals of Surgical Oncology, 1996, 3, 393-399.	1.5	53
46	Multi-modal treatment for metastatic renal cancer: the role of surgery. World Journal of Urology, 2010, 28, 295-301.	2.2	46
47	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydrataseâ€“Deficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2910-2919.	7.0	45
48	Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. Scientific World Journal, The, 2007, 7, 768-778.	2.1	43
49	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European Urology Focus, 2017, 3, 421-427.	3.1	43
50	Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. European Urology, 2018, 73, 53-59.	1.9	41
51	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clinical Genitourinary Cancer, 2019, 17, e678-e688.	1.9	41
52	Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. Journal of Urology, 2015, 193, 1911-1917.	0.4	40
53	Differentiation of Clear Cell Renal Cell Carcinoma From Other Renal Cortical Tumors by Use of a Quantitative Multiparametric MRI Approach. American Journal of Roentgenology, 2017, 208, W85-W91.	2.2	40
54	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. European Urology Focus, 2019, 5, 642-649.	3.1	40

#	Article	IF	Citations
55	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. Journal of Urology, 2014, 191, 914-919.	0.4	39
56	Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. Journal of Surgical Oncology, 2016, 114, 375-379.	1.7	39
57	Surgical Intervention in Patients with Metastatic Renal Cancer: Metastasectomy and Cytoreductive Nephrectomy. Urologic Clinics of North America, 2008, 35, 679-686.	1.8	38
58	Adult Prostate Sarcoma: The Memorial Sloan Kettering Experience. Urology, 2014, 84, 624-628.	1.0	38
59	Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. Journal of Urology, 2015, 194, 310-315.	0.4	36
60	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	1.9	35
61	New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors. Urology, 2015, 86, 1137-1145.	1.0	34
62	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 276-278.	2.5	34
63	Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. Journal of Urology, 2018, 199, 921-926.	0.4	34
64	Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival. American Journal of Roentgenology, 2016, 206, 1023-1030.	2.2	33
65	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical Genitourinary Cancer, 2019, 17, 373-379.e4.	1.9	33
66	Partial nephrectomy for renal cancer: Part I. BJU International, 2010, 105, 1206-1220.	2.5	32
67	Impact of a Common Clinical Pathway on Length of Hospital Stay in Patients Undergoing Open and Minimally Invasive Kidney Surgery. Journal of Urology, 2014, 191, 1225-1230.	0.4	32
68	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. Clinical Genitourinary Cancer, 2020, 18, 387-394.	1.9	32
69	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European Urology Focus, 2017, 3, 590-598.	3.1	31
70	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. Journal of Urology, 2018, 200, 275-282.	0.4	31
71	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. ELife, 2019, 8, .	6.0	31
72	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. Urology, 2015, 85, 596-604.	1.0	30

#	Article	IF	Citations
73	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	7.0	30
74	Positive Urinary Cytology Following a Complete Response to Intravesical Bacillus Calmette-Guerin Therapy: Pattern of Recurrence. Journal of Urology, 1994, 152, 382-387.	0.4	29
75	Localized renal cell carcinoma. Current Treatment Options in Oncology, 2001, 2, 447-455.	3.0	29
76	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus, 2018, 4, 986-994.	3.1	29
77	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clinical Genitourinary Cancer, 2019, 17, 268-274.e1.	1.9	29
78	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. Journal of Urology, 2015, 194, 304-309.	0.4	28
79	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	3.1	28
80	Metastatic Carcinoid Tumor of the Prostate. Journal of Urology, 2002, 167, 2526-2527.	0.4	27
81	Open partial nephrectomy: an essential operation with an expanding role. Current Opinion in Urology, 2007, 17, 309-315.	1.8	27
82	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. Journal of Urology, 2015, 193, 436-442.	0.4	27
83	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. Journal of Surgical Oncology, 2016, 114, 764-768.	1.7	26
84	The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 239.e1-239.e8.	1.6	25
85	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 532.e7-532.e13.	1.6	25
86	The Role of Surgery inÂthe Management of Early-Stage RenalÂCancer. Hematology/Oncology Clinics of North America, 2011, 25, 737-752.	2.2	23
87	Long-term mortality in patients with germ cell tumors: Effect of primary cancer site on cause of death. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 26.e9-26.e15.	1.6	23
88	Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. Canadian Urological Association Journal, 2014, 8, 675.	0.6	22
89	Surgical Treatment of Tumors Involving Kidneys With Fusion Anomalies: A Contemporary Series. Urology, 2016, 98, 97-102.	1.0	22
90	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. European Urology, 2022, 81, 570-573.	1.9	22

#	Article	IF	Citations
91	Partial nephrectomy for renal cancer (part II): the impact of renal ischaemia, patient preparation, surgical approaches, management of complications and utilization. BJU International, 2010, 105, 1494-1507.	2.5	21
92	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 35.e1-35.e5.	1.6	21
93	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	3.3	21
94	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	5.4	20
95	TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin. Prostate, 1994, 24, 237-243.	2.3	19
96	Partial and Radical Nephrectomy for Unilateral Synchronous Multifocal Renal Cortical Tumors. Urology, 2015, 85, 1404-1410.	1.0	19
97	Estimated glomerular filtration rate, renal scan and volumetric assessment of the kidney before and after partial nephrectomy: a review of the current literature. Minerva Urology and Nephrology, 2017, 69, 539-547.	2.5	19
98	Subcentimeter Pulmonary Nodules are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma. Journal of Urology, 2015, 193, 776-782.	0.4	18
99	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. European Journal of Surgical Oncology, 2019, 45, 1983-1992.	1.0	18
100	Results of laparoscopic pelvic lymphadenectomy in patients at high risk for nodal metastases from prostate cancer. Annals of Surgical Oncology, 1998, 5, 173-180.	1.5	16
101	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	5.4	16
102	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 24-29.	0.4	15
103	Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. European Journal of Cancer, 2016, 59, 57-64.	2.8	15
104	The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. Journal of Urology, 2016, 195, 264-269.	0.4	15
105	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. British Journal of Anaesthesia, 2020, 125, e402-e404.	3.4	15
106	Urologic complications of major pelvic surgery. , 2000, 18, 216-228.		14
107	Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. European Urology Focus, 2018, 4, 100-105.	3.1	14
108	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 79.e11-79.e17.	1.6	14

#	Article	IF	Citations
109	The natural history of large renal masses followed on observation. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 362.e17-362.e21.	1.6	14
110	The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer, 1998, 82, 389-394.	4.1	14
111	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Modern Pathology, 2022, 35, 825-835.	5.5	14
112	Myocutaneous Flaps in Genitourinary Oncology. Journal of Urology, 1994, 151, 920-924.	0.4	13
113	Open Mini-Flank Partial Nephrectomy: An Essential Contemporary Operation. Korean Journal of Urology, 2014, 55, 557.	1.2	13
114	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. World Journal of Urology, 2017, 35, 51-56.	2.2	13
115	Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy. Nature Reviews Urology, 2004, 1, 26-30.	1.4	12
116	Functional preservation in patients with renal cortical tumors: The rationale for partial nephrectomy. Current Urology Reports, 2008, 9, 15-21.	2.2	12
117	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. International Scholarly Research Notices, 2014, 2014, 1-6.	0.9	12
118	Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. World Journal of Urology, 2015, 33, 2023-2029.	2.2	12
119	Patterns of surveillance imaging after nephrectomy in the <scp>M</scp>edicare population. BJU International, 2016, 117, 280-286.	2.5	12
120	Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. World Journal of Urology, 2016, 34, 539-544.	2.2	12
121	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. Cancer, 2017, 123, 2452-2458.	4.1	12
122	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 5595-5606.	7.0	12
123	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer, 2021, 127, 3946-3956.	4.1	12
124	Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1075-1083.	1.5	11
125	Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 257-263.	2.2	11
126	The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 302.e1-302.e6.	1.6	11

#	Article	IF	Citations
127	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European Urology Focus, 2022, 8, 1278-1288.	3.1	11
128	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. European Urology Oncology, 2020, 3, 365-371.	5.4	10
129	Open partial nephrectomy. Personal technique and current outcomes. Archivos Espanoles De Urologia, 2011, 64, 571-93.	0.2	10
130	Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. Expert Review of Anticancer Therapy, 2006, 6, 1745-1751.	2.4	9
131	Neutrophil-Lymphocyte Ratio in Small Renal Masses. ISRN Urology, 2014, 2014, 1-5.	1.5	9
132	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology, 2020, 136, 169-175.	1.0	9
133	Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry. Journal of Urology, 2020, 203, 1094-1100.	0.4	9
134	Clinicopathologic Features of Renomedullary Interstitial Cell Tumor Presenting as the Main Solid Renal Mass. Urology, 2014, 83, 1104-1106.	1.0	8
135	Influence of renal biopsy results on the management of small kidney cancers in older patients: Results from a population-based cohort. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 604.e1-604.e9.	1.6	8
136	The contemporary role of lymph node dissection in the management of renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 335-342.	2.0	8
137	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 916-923.	1.6	8
138	The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. Clinical Genitourinary Cancer, 2018, 16, 191-196.	1.9	7
139	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	9.4	7
140	Oncological outcomes of partial nephrectomy for renal carcinoma greater than 4â€Šcm. Current Opinion in Urology, 2011, 21, 362-367.	1.8	6
141	Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. World Journal of Urology, 2016, 34, 1667-1672.	2.2	6
142	Importance of wide reâ€resection in adult spermatic cord sarcomas: Report on oncologic outcomes at a single institution. Journal of Surgical Oncology, 2018, 117, 1464-1468.	1.7	6
143	The association of renal cell carcinoma with gastrointestinal stromal tumors. Journal of Surgical Oncology, 2018, 117, 1716-1720.	1.7	6
144	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 811.e9-811.e16.	1.6	6

#	Article	IF	Citations
145	Preoperative nomogram predicting 12-year probability of metastatic renal cancer â€“ evaluation in a contemporary cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 853.e1-853.e7.	1.6	6
146	A comparison of oncologic and functional outcomes in patients with pt3a renal cell carcinoma treated with partial and radical nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 777-783.	1.5	6
147	Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. European Urology Focus, 2019, 5, 977-979.	3.1	5
148	Renal cell carcinoma: Associations between tumor imaging features and epidemiological risk factors. European Journal of Radiology, 2020, 129, 109096.	2.6	5
149	Low yield of surveillance imaging after surgery for T1 kidney cancer. World Journal of Urology, 2016, 34, 949-953.	2.2	4
150	Juxtaglomerular Cell Tumor: A Rare, Curable Cause of Hypertension in a Young Patient. Urology, 2019, 134, 42-44.	1.0	4
151	Upper Tract Urothelial Carcinoma in a Patient With Horseshoe Kidney. Urology, 2020, 142, e20-e24.	1.0	4
152	Partial Nephrectomy: The Rationale for Expanding the Indications. Annals of Surgical Oncology, 2002, 9, 680-687.	1.5	4
153	A qualitative framework of non-selection factors for cytoreductive nephrectomy. World Journal of Urology, 2021, 39, 3359-3365.	2.2	3
154	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma â€“ An exploratory analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e17-791.e24.	1.6	3
155	Is laparoscopic partial nephrectomy as effective as open partial nephrectomy in patients with renal cell carcinoma?. Nature Reviews Urology, 2008, 5, 12-13.	1.4	2
156	Editorial Comment. Urology, 2009, 73, 1082.	1.0	2
157	Editorial Comment. Urology, 2009, 73, 1297-1298.	1.0	2
158	Delayed systemic treatment in metastatic renal-cell carcinoma. Lancet Oncology, The, 2016, 17, 1187-1189.	10.7	2
159	Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. PLoS ONE, 2017, 12, e0180350.	2.5	2
160	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	2.5	2
161	Renal tumours: developing understanding leads to developments in surgical treatment. BJU International, 2006, 97, 9-10.	2.5	1
162	To Clamp or Not To Clamp the Main Renal Artery: The Debate Continues. European Urology, 2014, 66, 720-721.	1.9	1

#	Article	IF	Citations
163	Reply to Williamson S.R. What is the malignant potential of clear cell papillary renal cell carcinoma? Urol Oncol 2016; 34: 420. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 581-582.	1.6	1
164	Progression from tubulovillous adenoma to high-grade adenocarcinoma in Indiana pouch urinary diversion. Urology Case Reports, 2018, 16, 129-131.	0.3	1
165	Editorial Comment on: Treatment Trends and Long-Term Survival Associated with Cryotherapy and Partial Nephrectomy for Small Renal Masses in the National Cancer Database Using Propensity Score Matching by Kitley et al.(From: Kitley W, Sulek J, Sundaram C, et al. J Endourol 2019;33:408â€“414; DOI:) Tj ETQq1 1 0.784314 rgBT	2.1	1
166	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.6	1
167	The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 196.e9-196.e14.	1.6	1
168	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
169	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 395-395.	1.6	1
170	Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 513-513.	1.6	1
171	RE: LAPAROSCOPIC RADICAL NEPHRECTOMY: CANCER CONTROL FOR RENAL CELL CARCINOMA. Journal of Urology, 2002, 168, 1109-1109.	0.4	0
172	Renal cryoablation: a new treatment in need of careful clinical investigation. Nature Clinical Practice Oncology, 2006, 3, 286-287.	4.3	0
173	Editorial Comment. Urology, 2014, 84, 1406-1407.	1.0	0
174	Handling patients with growing small renal masses. Canadian Urological Association Journal, 2014, 8, 28.	0.6	0
175	Editorial Comment. Urology, 2014, 83, 849-850.	1.0	0
176	Editorial Comment. Urology, 2015, 85, 1422-1423.	1.0	0
177	Reply. Urology, 2015, 85, 603-604.	1.0	0
178	Editorial Comment. Urology, 2016, 93, 129.	1.0	0
179	Editorial Comment. Journal of Urology, 2017, 198, 35-35.	0.4	0
180	Editorial Comment. Journal of Urology, 2018, 199, 400-400.	0.4	0

#	Article	IF	Citations
181	Editorial Comment. Journal of Urology, 2018, 199, 59-59.	0.4	0
182	Primary Renal Well-differentiated Neuroendocrine Tumor Extending Into the Inferior Vena Cava. Urology, 2020, 135, e2-e4.	1.0	0
183	Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. Canadian Urological Association Journal, 2020, 15, E103-E109.	0.6	0
184	EDITORIAL COMMENT. Urology, 2020, 136, 167-168.	1.0	0
185	EDITORIAL COMMENT. Urology, 2021, 148, 190.	1.0	0
186	Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).. Journal of Clinical Oncology, 2021, 39, 353-353.	1.6	0
187	Open partial nephrectomy with kidney split: Effective surgical approach to resect completely endophytic tumors. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 371.e1-371.e5.	1.6	0
188	Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management. Urology, 2021, , .	1.0	0
189	Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis.. Journal of Clinical Oncology, 2014, 32, 432-432.	1.6	0
190	Neutrophil-lymphocyte ratio in small renal masses.. Journal of Clinical Oncology, 2014, 32, 522-522.	1.6	0
191	Association of baseline health and gender with small renal mass pathology.. Journal of Clinical Oncology, 2014, 32, 515-515.	1.6	0
192	Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation.. Journal of Clinical Oncology, 2015, 33, 406-406.	1.6	0
193	The immune landscape of renal cell carcinoma and its association with intratumoral clonality.. Journal of Clinical Oncology, 2016, 34, 605-605.	1.6	0
194	Comparing surgical tissue versus biopsy tissue in the development of a clear cell renal cell carcinoma xenograft model.. Journal of Clinical Oncology, 2016, 34, 519-519.	1.6	0
195	Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 512-512.	1.6	0
196	Editorial Comment. Journal of Urology, 2019, 201, 708-708.	0.4	0
197	Editorial Comment. Journal of Urology, 2019, 202, 1125-1126.	0.4	0
198	Editorial Comment. Journal of Urology, 2020, 204, 441-441.	0.4	0